UNSPSC 51172306: Sodium polystyrene sulfonate

This classification denotes an electrolyte replacement agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1699G8679Z. European Medicines Agency schedules Sodium polystyrene sulfonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15321MIG. Sodium polystyrene sulfonate generally arises in the molecular formula (C8H8(C2H3)XL)N.(C8H8O3S)N.NA. The term 'sodium polystyrene sulfonate' is an FDA designation.

As of Q4 2014, SODIUM POLYSTYRENE SULFONATE remains the US FDA Preferred Term for this commodity. Sodium polystyrene sulfonate bears US NLM identifiers UMLS ID C0142915 and NCI Concept Code C29461. SMILES: C=CC1=CC=CC=C1S(=O)(=O)[O-].[CA+2].

UNSPSC 51172306 Sodium polystyrene sulfonate (Commodity) encompasses pharmaceutical products and related supplies procured by state and local health and criminal-justice agencies, though recent solicitation activity shows limited direct connection to the specific compound. State and local buyers under this code include county corrections departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions. The work being solicited spans drug-testing services, pharmacy benefit programs, and generic pharmaceutical supply agreements that may include electrolyte-management compounds and related medical products as part of broader therapeutic formularies. Issuing bodies include county community supervision and corrections departments, state health commissions, and multistate cooperative purchasing organizations.

Recent opportunities span Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 (due July 23, 2026) for offender specimen collection and drug testing services, estimated at $600,000 over two years with three optional one-year renewals, requiring lab certification and approximately 25,031 annual tests across five- and six-panel screens with confirmation testing. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, an exploratory phase to inform future formal procurement strategy without disclosed budget or timeline commitments. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across state and local facilities in Minnesota and Oregon, with contract commencement July 1, 2026 and evaluation weighted 75 percent on price competitiveness.